In a study involving 8-week-old male db/db mice, administration of SGLT2 inhibitor Empagliflozin and DPP4 inhibitor Linagliptin resulted in enhanced autophagy in renal podocytes, indicating that both drugs can attenuate the progression of diabetic nephropathy through the autophagic pathway. The gene discussed is SLC5A2; the disease is diabetic kidney disease.